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Introduction
The Escherichia coli heat-labile enterotoxin (LT) and Vibrio cholerae toxin (CT) are two bacterial toxins with a powerful adjuvant capacity [1] . Both toxins consist of a monomeric A subunit with enzymatic activity and of a homo-pentameric ring of B subunits which binds to the cell surface ganglioside GM1. The enzymatic activity of these toxins results in a persistent activation of adenylate cyclase and the increase of cytosolic cAMP [2] , which disrupts cell homeostasis with a variety of toxic effects [2, 3] . The high toxicity of LT and CT has stimulated the search for mutants with low or no toxicity retaining their immunostimulatory capacity. The LTK63 (Ser to Lys substitution at position 63 of the A subunit of LT) and LTR72 (Ala to Arg substitution at position 72 of the A subunit of LT) toxoids are two LT mutants with none or a reduced enzymatic activity and toxicity, respectively [4, 5] . However, the attenuation of the enzymatic activity of these mutants is associated with some decrease in their adjuvanticity [4, 5] . Thus, it becomes important to understand the mechanisms that link enzymatic activity and adjuvanticity of LT. Most of the present knowledge of the adjuvant effects of these molecules is based on experiments with animals immunized mucosally, mainly i.n. [6] . However, some reports from animal [7] and human studies [8, 9] have raised concerns on the safety of these molecules after i.n. administration. LT and LT mutants are also strong adjuvants following parenteral administration [10, 11] .
However, if little is still known on the fine molecular mechanisms underlying the mucosal adjuvanticity of LT and LT mutants, even less information is available on the effects triggered by these molecules after systemic administration.
Several studies point to DC as the principal cellular target of LT and CT adjuvanticity in vivo [12, 13] . Both toxins induce the maturation of DC, increasing their antigen presentation capability, their migration to the lymph nodes and their interaction with naïve T cells [14] . In addition, CT and LT may act directly on lymphocytes inducing their activation and/or cell death [3, 15, 16] . We have previously shown that administration of LT promotes an intense but incomplete apoptosis of lymphocytes [5, 16] . This, together with the capacity of the toxin to stimulate the remaining lymphocytes [15] , may explain the apparent paradox that an agent which such a potent pro-apoptotic activity can be an adjuvant. An interesting observation is that the LT-mediated cell death is only observed after its systemic administration [3] , suggesting that the immunomodulatory properties of LT are highly influenced by the route of toxin delivery. Because of the glucocorticoid-mediated effect of LT on apoptosis [3, 16] , our interest was focused on the glucocorticoid-induced TNFR-related protein (GITR), a member of the TNFR superfamily that is constitutively expressed at high levels in Tregs and at low levels on conventional CD4 +
CD25
-and CD8 + T cells where it is rapidly upregulated after activation [17] . Since GITR-GITRL signalling pathways can influence the activation and activity of effector and regulatory T cells as well as DC [17] [18] [19] , we have analyzed the possible role of GITR in the systemic or mucosal adjuvanticity of LT in comparison to the enzymatically inactive LTK63 mutant. We report here that the systemic adjuvanticity of LT associated with the enzymatic activity is linked to their capacity to induce the expression of GITR in T cells. We further demonstrate that the mechanisms of adjuvanticity of these immunostimulatory molecules can be distinct at different anatomical sites.
Results
Systemic, but not mucosal, administration of LT induces the expression of GITR in naïve T cells. Figure 1A) . Remarkably, the number of CD4 + T cells expressing high levels of GITR remained unchanged after LT administration ( Figure 1A ).
Since LT promotes an intense T-cell apoptosis [3, 16] , we explored whether the maintenance in the number of CD4 + GITR high cells after LT treatment could reflect an enhanced resistance of these cells to LT induced apoptosis and/or an expansion of this cell population. For that, we explored first the effects of LT in BALB/c mice after bilateral adrenalectomy, which severely impairs LT-induced lymphocyte apoptosis [3, 16] . In these adrenalectomized mice, f.p. treatment with LT did not modify significantly Figure 1A ). In contrast, the number of CD4 + CD25 -GITR high cells was increased in these mice ( Figure 1A ). In addition, no differences in the susceptibility of peripheral CD4 + T cells to f.p. LTinduced apoptosis were found between Sv129-GITR -/-mice and wild type littermates Figure 1E ) and which are refractory to the LT-induced apoptosis of mature T cells [16] .
LT also promoted the expression of GITR in inguinal and mesenteric lymph node cells and purified CD4 + CD25 -spleen T cells stimulated in vitro with LT during 24 hrs (Table   1) (Table 1) .
T-cell induction of GITR by LT requires its enzymatic activity and is specific of this adjuvant.
To explore whether the enzymatic activity of LT was required to induce the expression of GITR in CD4 + T cells, bilateral adrenalectomized BALB/c mice were injected into the f.p. with 1 or 30 μg of either the enzymatically inactive or the partially active LTK63 and LTR72 mutants, respectively [4, 5] . At the higher dose, but not with the lower dose, of the toxins the partially active LTR72 mutant, but not the fully detoxified LTK63 mutant, was able to induce GITR expression in naïve CD4 
Discussion
The unique property of LT to act as a potent mucosal and systemic adjuvant has stimulated many studies aimed at understanding its mechanism of action [21] ). Here, we demonstrate that LT induces the expression of GITR, but not other activation markers, on T cells when administered systemically by a mechanism that requires the enzymatic activity of the toxin and is independent of endogenous glucocorticoids. This effect seems specific of LT since is not observed with other commonly used adjuvants or immune stimulators. The induction of GITR expression in CD4 + T cells accounts for the systemic adjuvanticity of LT which is associated to its enzymatic activity. Finally, the inability of LT to promote GITR expression in Peyer´s Patches T cells after its mucosal administration and the fact that wild type and GITR -/-mice respond equally to i.n.
administered antigens using either LT or LTK63 as adjuvants, clearly indicates that the mechanisms of adjuvanticity of these toxins are highly influenced by their route of administration.
We describe a novel mechanism of systemic adjuvanticity of LT linked with the capacity of the toxin to induce the expression of key costimulatory molecules, such as ] supports the possibility of using these adjuvants via the parenteral route. In this light, our study provides insights into the understanding of immunomodulatory properties of LT and related toxins that may lead to the harnessing of such activities in safer forms.
Materials and Methods

Mice and surgery.
BALB/c mice were obtained from Harland Iberica (Barcelona, Spain Research, Australia), to obtain double-Tg mice. Sv129-GITR -/-mice were generated by homologous recombination as previously described [31] .
Adrenal glands were removed as described [3] . LT toxin was administered 2 days after surgery.
All experiments were performed in 6-8 wk old animals and approved by the Universidad de Cantabria Institutional Laboratory Animal Care and Use Committee.
Adjuvants and immunization protocols.
LT and their mutants, MF59 and Alum were obtained from Novartis Vaccines after the AHGG boost, as described [20] .
In some experiments, Sv129-GITR -/-mice and wild type littermates were immunized i.p. with 100 µg of OVA together with either 1 µg of LT or 5 µg of LTK63.
A similar boost was performed 20 days later. As a control, mice were immunized with 100 µg of OVA-CFA and boosted with 100 µg of OVA-IFA 20 days later. The mucosal adjuvanticity of toxins were tested by immunizing i.n. Sv129-GITR -/-mice and wild type littermates on days 0 and 21 with 10 µg of toxins and 10 µg of OVA, or with antigen alone. In all experiments, the titres of IgA, IgG and IgG subclass specific anti-OVA Abs in sera were measured by ELISA 15 days after the boost, as described [5] .
Induction of apoptosis by LT.
Sv129-GITR -/-mice and wild type littermates were injected into the f.p. with 1 μg of LT and the induction of apoptosis of CD4 + T cells was evaluated 72 hrs later as described previously [3, 16] .
Flow cytometry studies.
Frequencies of lymphocyte populations were evaluated in the spleen, mesenteric In vivo proliferation assay.
Mice received an i.p. injection of 1 mg of BrdU (Sigma) prior to the treatment with 1 µg LT and maintained with BrdU in the drinking water (0.8 mg/ml) during the following three days. The incorporation of BrdU in mature B and T spleen cells was evaluated by flow cytometry 72 hrs after LT administration, as described previously [32] .
Treatment with mAbs.
For CD4 + CD25 + T cell depletion, mice received one daily i.p. injection of 0.2 mg of anti-CD25 mAb (clone PC61) during three days one week before the immunization with AHGG or DHGG. The efficiency of the treatment was confirmed by flow cytometry. In some experiments, mice received i.p. 1 mg of an agonistic anti-GITR mAb (DTA-1) [18] , generously provided by Dr Simon Sakaguchi (Kyoto University, Kyoto, Japan), at the time of DHGG tolerization.
Real time RT-PCR assays.
Total RNA was obtained from the spleen of bilateral adrenalectomized Sv129-GITR -/-mice and wild type littermates 5 days after i.p. injection of 1 μg of LT or PBS and used for cDNA synthesis with a RT-PCR kit (Fermentas, Quimigen S.L., Madrid).
Quantitative, real time PCR was conducted on a MX-3000P Stratagene instrument (La Jolla, CA) using specific TaqMan POMC expression assays (Applied Biosystems, Life Technologies). Results (in triplicate) were normalized to GAPDH expression. Data were expressed as mean fold change relative to control samples (n= 5 mice/group).
Statistical analysis.
Statistical analysis was performed using the two-tailed Student´s t test or the MannWhitney test. Probability values <0.05 were considered significant. [27] Tamura, S., Funato, H., Nagamine, T., Aizawa, C. and Kurata, T., Sv129-wt Sv129-GITR -/-*** ***
